Processa Pharmaceuticals (PCSA) PT Lowered to $3 at Oppenheimer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts PCSA Hot Sheet
Price: $1.86 -4.12%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 17 | Down: 26 | New: 12
Join SI Premium – FREE
Oppenheimer analyst Francois Brisebois lowered the price target on Processa Pharmaceuticals (NASDAQ: PCSA) to $3.00 (from $5.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Processa Pharmaceuticals names four executives to leadership roles
- Twilio (TWLO) PT Raised to $320 at Tigress Financial Partners
- Sprout Social Inc. (SPT) PT Raised to $15 at Stifel
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
